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Abstract
Background: Calcitonin has been demonstrated to have chondroprotective effects under pre-clinical settings. It is
debated whether this effect is mediated through subchondral-bone, directly on cartilage or both in combination.
We investigated possible direct effects of salmon calcitonin on proteoglycans and collagen-type-II synthesis in
osteoarthritic (OA) cartilage.
Methods: Human OA cartilage explants were cultured with salmon calcitonin [100 pM-100 nM]. Direct effects of
calcitonin on articular cartilage were evaluated by 1) measurement of proteoglycan synthesis by incorporation of
radioactive labeled
35SO4 [5 μCi] 2) quantification of collagen-type-II formation by pro-peptides of collagen type II
(PIINP) ELISA, 3) QPCR expression of the calcitonin receptor in OA chondrocytes using four individual primer pairs,
4) activation of the cAMP signaling pathway by EIA and, 5) investigations of metabolic activity by AlamarBlue.
Results: QPCR analysis and subsequent sequencing confirmed expression of the calcitonin receptor in human
chondrocytes. All doses of salmon calcitonin significantly elevated cAMP levels (P < 0.01 and P < 0.001). Calcitonin
significantly and concentration-dependently [100 pM-100 nM] induced proteoglycan synthesis measured by
radioactive
35SO4 incorporation, with a 96% maximal induction at 10 nM (P < 0.001) corresponding to an 80%
induction of 100 ng/ml IGF, (P < 0.05). In alignment with calcitonin treatments [100 pM-100 nM] resulted in 35%
(P < 0.01) increased PIINP levels.
Conclusion: Calcitonin treatment increased proteoglycan and collagen synthesis in human OA cartilage. In
addition to its well-established effect on subchondral bone, calcitonin may prove beneficial to the management of
joint diseases through direct effects on chondrocytes.
Background
Osteoarthritis (OA) is the most common disease of the
joints [1], and each year half-million Americans undergo
total joint replacement [2]. Key characteristic of the dis-
ease are the accelerated degeneration of articular carti-
lage, changes in the matrix structure, and sclerosis of
the subchondral bone. At present, there are no structure
modifying drugs (SMOAD) accepted by either FDA
(The US Food and Drug Administration) or EMEA (The
European Medicines Agency). OA is a complicated con-
dition of the entire joint, involving cartilage, bone, and
the synovium, which highlights the complexity of the
disease and may provide some understanding of why
current treatments have not been successful [2-4].
The key components of articular cartilage are type II
collagen and the proteoglycan aggrecan, which together
constitutes 90% dry weight of healthy cartilage [5]. Cur-
rent drug development strategies have particularly
focused on inhibition of the enzymes responsible for
degradation of these extra-cellular matrix (ECM) mole-
cules, mainly the matrix metalloproteinases (MMPs) and
the aggrecanases a disintegrin and metalloproteinase
with thrombospondin motifs (ADAM-TS), which have
resulted in potent MMP and aggrecanase inhibitors [6].
However, besides preclinical efficacy, these treatment
opportunities have yet to demonstrate clinical efficacy
and have additionally been implicated in the develop-
ment of adverse musculoskeletal events [2].
Calcitonin is a 32-amino acid peptide hormone pro-
duced by the parafollicular cells in the thyroid gland
that possess potent anti-resorptive effects by binding to
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in the treatment of osteoporosis (OP) for more than 30
years [8]. Various sources of calcitonin are found; of
which salmon calcitonin is the most potent [7]. The
effect of calcitonin on chondrocytes and cartilage meta-
bolism is less investigated. Recently, it was proposed
that articular chondrocytes express the calcitonin recep-
tor and respond directly to calcitonin [9]. This has how-
ever been debated [10].
Salmon calcitonin has been shown to have chondro-
protective effects in a range of animal models of OA.
More specifically, calcitonin has been shown to counter
the progression of joint lesions in a range of preclinical
models, both traumatic and non-traumatic [11,12], sug-
gesting potential chondroprotective effects. However,
whether this apparent chondroprotective effect is
mediated through modulation of subchondral bone
turnover [10], either in part by effecting the peri-articu-
lar bone as suggested by Lin et al.a n dB e h e t set al
[10,11] or as a direct effect of calcitonin articular carti-
lage, remains to be elucidated. A small number of inves-
tigators have focused their attention on the direct effects
of calcitonin on articular cartilage of various species
other than human, and even fewer has focused on cul-
tured human OA chondrocytes in vitro,a ss u m m a r i z e d
in [13]. The direct effect on human osteoarthritic articu-
lar cartilage with chondrocytes anchored in their natural
environment remains to be addressed.
Articular cartilage explants have been shown to be a
useful in vitro model of cartilage degradation and for-
mation [14-18] where direct effects of new treatments
on articular cartilage can be assessed. Compared to
cultures of isolated chondrocytes, this model offers the
advantage that the chondrocyte phenotype is preserved
along with the intact ECM holding its natural integ-
rins, inhibitors and growth factors, thus allowing for
direct investigations of an in vivo-like situation. Apply-
ing the human articular cartilage explants model, we
investigated the potential anabolic actions of calcitonin
on the two major protein components in adult human
OA articular cartilage, namely collagen type II and
proteoglycans.
Methods
All experiments were carried out using GLP and
reagents of analytic grade. The human OA cartilage
used for the experiments was obtained from female
patients between the ages of 60-77 years undergoing
total knee arthroplasty. The patients were informed by
both oral and written communication at the hospital
and gave their written consent before entering study,
which was approved by the Capital Region of Denmark,
DK-3400, approval number HD-2007-0084.
Preparation of articular cartilage explants
Human OA articular cartilage from weight bearing
uneroded areas with a normal smooth surface and hard
texture was isolated and used for the experiments. Articu-
lar cartilage was cut into homologues explants, weighed
(20 ± 2 mg wet weight) and placed in 96-well plates, and
cultured in six-replicates under the following conditions at
37°C, 5% CO2 in serum-free medium D-MEM:F12 con-
taining penicillin and streptomycin (Life Technologies,
US), and to fortify the cultures in a controlled manner the
medium was supplemented with 2% Ultrose G (Pall Life
Sciences, FR). The cultures were repeated with five differ-
ent patients on individual plates. The explants were cul-
t u r e da sf o l l o w s :1 )i nm e d i u ma sc o n t r o l ,2 )i nm e d i u m
with different doses of salmon calcitonin [0.1-100 nM]
(Sigma-Aldrich, UK), 3) in medium with 100 ng/mL IGF
(Sigma-Aldrich, UK) as positive control [19]. To represent
the situation of complete metabolic inactivation, six
explants were placed in cryo-tubes (Nunc, DK), frozen in
liquid N2, and thawed at 37°C in water-bath for three
repeated freeze-thaw cycles, allowing investigations of
chondrocyte versus non-chondrocyte mediated effects.
These explants were cultured in medium only. The condi-
tioned medium was replaced every 2
nd to 3
rd day for six-
teen days and the collected conditioned medium was
stored frozen at -20°C until further analysis.
Investigation of cell viability
Cell viability was examined on the last day of culture
using the AlamarBlue colorimetric assay (Invitrogen,
DK). In brief, AlamarBlue solution was diluted to 10%
with the respective refreshed treatments of the cartilage
explants and incubated with the cartilage explants for
three hours. The fluorescence was measured at 540 nm
and 650 nm.
Radioactive labeling by
35SO4
Formation of proteoglycans was followed by radioactive-
labeled precursor incorporation of
35S as liquid sulfate
(Amersham Biosciences, US). On day sixteen of culture,
explants were pulsed with 5 μCi
35SO4 added to the
refreshed conditioning medium to each culture and
incubated for 24 hours more. After pulsing, the explants
were washed 5 times with PBS and the explants were
dissolved for 48 h at 2-8°C in 4 M GuHCl (buffer: 50
mM sodium acetate, pH 5.8, containing 10 mM EDTA
and 0.1 M caproic acid) to release all soluble proteogly-
cans like chondrotin sulphate and keratin sulphate side
chains [20]. The incorporation of radioactive-labeled
35SO4 was quantified independently for each proteogly-
can extract of the cartilage explants samples using liquid
scintillation counting and normalized to the amount of
cultured cartilage.
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The quantification of pro-peptides from the N-terminal of
collagen type II (PIINP) by ELISA (IDS Ltd., UK) was used
for the assessment of collagen type II formation from the
conditioned medium at day 16 of culture. The PIINP
ELISA is a competitive enzyme-linked immunoassay based
on a monoclonal antibody (F7504) recognizing a linear
sequence GPQGPAGEQPGRGDR located in the center of
the N-terminal pro-peptide of collagen type II [21].
RNA extraction
The human articular cartilage (150 mg wet weight) was
obtained in RNALater (Applied Biosystems, UK) directly
from the operation theater and pulverized in liquid
nitrogen by the Bessman Tissue Pulverizer (Spectrum
Laboratories, US). Lysis of cells and RNA extraction was
performed using the PicoPure™ RNA Isolation Kit
(Molecular Devices, US). On column DNase digestion
was performed for 7.5 minutes with DNA-free (Ambion,
UK). Human osteoclasts were retrieved as described pre-
viously [9,22], and the RNA purified using the RNA iso-
lation kit (Qiagen, UK). The RNA was quantified using
a NanoDrop-1000 Spectrophotometer (Thermo Fisher
Scientific Inc, US).
cDNA synthesis and QPCR
cDNA for QPCR was prepared using Transcriptor First
Strand cDNA Synthesis Kit (Roche Diagnostics, US)
with anchored-oligo (dT)18 primer and random hexamer
primers. No template controls (NTC) were prepared
without the addition of reverse transcriptase to the
cDNA synthesis. QPCR was performed on a Stratagene
Mx3000Pro using Brilliant SYBR Green II Mastermix
(Stratagene Agilent Technologies, US). SYBR Green
melting temperatures (Tm) of the products were deter-
mined for all calcitonin receptor primer pairs by QPCR
analysis on a plasmid encoding the entire calcitonin
receptor. The calcitonin receptor primers were designed
to the coding region of the calcitonin receptor from the
accession number NCBI: [NM_001742] and primers of
SURF1 was used as a housekeeping gene, see table 1 for
primer details. Primer pairs were used in concentrations
of 200 nM, and all analysis were performed in dupli-
cates. Validity of QPCR products were confirmed based
on SYBR green melting curves, visualization on a 2%
agarose gel stained with ethidium bromide, and finally
sequencing of calcitonin receptor products (Eurofins
MWG Operon, DE).
Intracellular signaling
Response to calcitonin
Human OA articular cartilage was obtained from patients
undergoing total knee arthroplasty from the patient group
mentioned above. Articular chondrocytes were isolated
from the ECM by enzymatic digestion with 0.5% trypsin
(Sigma-Aldrich, UK) for 30 minutes and 0.5% collagenase
(Wako, DE) for 4 hours at 37°C. Chondrocytes were
obtained after filtration and centrifugation at 1600 × g for
10 min. The pellet was re-suspended in a-MEM contain-
ing 10% foetal bovine serum (FBS) (Sigma-Aldrich, UK),
and sub-cultured for four days at 37°C, 5% CO2. The cells
were lifted, centrifuged, and cultured under serum-free
conditions for 24 hours, and subsequently pre-inhibited
for one hour with 100 mM 3-isobutyl-1-methylxanthine,
IBMX (Sigma-Aldrich, UK), and afterwards stimulated
with 1 pM-100 nM salmon calcitonin for 15 minutes.
IBMX [100 mM] was used alone as a background control.
Quantification of the intracellular second messenger
cAMP was performed according to the EIA kit protocol
(Amersham Biosciences, US).
After the first passage and centrifugation the chondro-
cytes regain their spherical appearance. In order to con-
firm that the isolated chondrocytes still expressed the
calcitonin receptor, immunocytochemistry was per-
formed using mouse calcitonin receptor antibody direc-
ted towards the human calcitonin receptor (AbD
Serotec, UK) on chondrocytes cultured in 96-well plates
parallel to the studies. Chondrocytes with a fibroblast-
like appearance did not react with the calcitonin recep-
tor antibody, whereas all the spherical cells did, these
results are not shown.
Antagonist competition binding
Chondrocytes were retrieved as described above. The
chondrocytes were seeded at a density of 40.000 cells/
Table 1 Location of primerpairs in the coding region of the human calcitonin receptor.
Gene Forward Reverse Product length Product Tm
SURF1 5-CAGCAGACCCAATGGAAC-3 5-CCAGGATGGTGACTCCC-3 238 bp ~83.6
Coll2A 5-AGGATGGTGACTCCCAAG-3 5-GTCCATGGGTGCAATGTCAA-3 136 bp ~83.5
CalcR 1 5-GACAACTGCTGGCTGAGTG-3 5-GAAGCAGTAGATGGTCGCAA-3 321 bp ~84.1
CalcR 2 5-TGATTCATTTCCAGGGCTTC-3 5-GCTGGTTCATTCCTCAGCTC-3 220 bp ~88.2
CalcR 3 5-GGTAACCCTGCACAAGAAC-3 5-AAGCGTTGCTTCTCAGTAAA-3 235 bp ~82.0
CalcR 4 5-ACACCGGCTGGAGTATTGTC-3 5-AAAATCCCCAGGGAAATCAC-3 257 bp ~79.8
Housekeeping gene: SURF1; Collagen type II: Coll2A; Calcitonin receptor 1-4: CalcR 1-4.
Length of PCR products, base pairs (bp) and melting temperature (Tm)
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incubated at 37°C, 5% CO2. The next day, all primary
chondrocytes were stimulated with 100 mM IBMX for
one hour. Subsequently, some cells were pre-incubated
with 100 nM the calcitonin receptor antagonist 8-32
sCT (Bachem, CH) + 100 mM IBMX for 30 minutes.
Other cells had refreshment of 100 mM IBMX for refer-
ence. Subsequently the antagonist treated cells were
incubated with 100 nM salmon calcitonin for 30 min.
A sap o s i t i v ec o n t r o l ,1 0 0μM forskolin, an activator of
adenylylcyclase, was used. In all instances the supple-
mented medium was preheated and the treatments
balanced in concentration so that only 50% of the med-
ium was changed during addition of the IBMX, antago-
nist or salmon calcitonin. After the last incubation, the
cells were subjected to lysis and the cAMP levels were
quantified as described above.
Statistics
R e s u l t sa r es h o w na sm e a n+S E M .A l lin vitro experi-
ments were conducted with a minimum of five repetitions
and all explants cultures in 6 replicates for each treatment.
The results shown from biochemical markers and incor-
poration are representative from one subject, a 78 year old
female, and comparable results were obtained from all
subjects. Differences between mean values were compared
group by group using Student’s two-tailed t-test for
unpaired observations using the GraphPad Prism software
and under assumption of normal distribution. Differences
were considered statistical significant if P < 0.05.
Results
Calcitonin stimulates proteoglycan synthesis in human
articular cartilage explants
The effects of salmon calcitonin on human articular carti-
lage proteoglycan synthesis were investigated in response
to different doses (100 pM-100 nM). Figure 1, shows the
proteoglycan synthesis under the different conditions as
determined by the levels of incorporated
35SO4.S i g n i f i -
cantly more sulfate was incorporated into the papain
extractable proteoglycans of the control explants com-
pared to metabolic inactive, non-cell-mediated back-
ground levels P < 0.001. The 10 nM salmon calcitonin
significantly induced a 96%, (P < 0.001), increase in pro-
teoglycan synthesis. All other concentrations, including
the very low 100 pM concentration, P < 0.05, increased
levels incorporated
35SO4 compared the vehicle control.
IGF was included as a positive control, which induced an
80% (P < 0.05) increase in proteoglycan synthesis.
Calcitonin stimulates cartilage formation measured by the
release of pro-peptides of collagen type II
To further assess the effect of salmon calcitonin on col-
lagen type II synthesis, the levels of PIINP in the
conditioned medium was quantified. As expected, the
positive control significantly increased the levels of
PIINP (P < 0.05), see figure 2. Doses of 10 and 100 nM
salmon calcitonin significantly stimulated the release of
pro-peptides of collagen type II measured by the PIINP
E L I S Ac o m p a r e dt oe x p l a n t sc u l t u r e di nm e d i u mo n l y ,
P < 0.01 and P < 0.05, respectively.
Human OA articular chondrocytes express the calcitonin
receptor
The expression of calcitonin receptor mRNA from
human articular chondrocytes (HCC) was investigated
by QPCR using four different calcitonin receptor primer
pairs designed to be intron spanning and to cover differ-
ent areas of the coding region of the human calcitonin
receptor. As a positive control, the expression of calcito-
nin receptor was analyzed in human osteoclasts (HOC),
and as negative controls NTC’sw e r ei n c l u d e d .T h e
expression of the housekeeping gene Surf1 was analyzed
in both HCC and HOC, and the expression of the
HCC-specific gene collagen type IIa was investigated in
the HCC. QPCR analysis using the four different calcito-
nin receptor primer-pairs showed the presence of the
calcitonin receptor mRNA in HCC in addition to the
HOC. The QPCR results were confirmed by sequencing
of the PCR products. Figure 3A shows a representative
image of the QPCR amplicons.
Figure 1 Calcitonin stimulates proteoglycan formation in
human osteoarthritic cartilage. Human OA articular cartilage
explants were cultured with or without doses of salmon calcitonin,
and on day 16 pulsed with 5 μCi
35SO4 for 24 hours. The
proteoglycans were extracted and the incorporation of
35SO4 were
followed by liquid scitillation counting. Insulin-like growth factor
(IGF) was used as a positive control to induce formation in articular
cartilage. The bars represent the mean value of count pr. minute,
cpm, from 6-replicates and the indivdual values were adjusted for
the amount of cultured cartilage. The errorbars are the standard
error of mean, SEM. The asterisks symbolize the levels of statistical
difference to the vehicle control, * P < 0.05, ***P < 0.001.
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Signaling of calcitonin through the calcitonin receptor and
binding to G-coupled receptors has previously been
shown to activate adenylylcyclase, resulting in increased
cAMP levels [23]. The response of cAMP levels to salmon
calcitonin stimulation of isolated HCC was investigated.
The chondrocytes were exposed to salmon calcitonin in
co-culture with [100 μM] IBMX, a non-specific inhibitor
of cAMP phosphodiesterases, hereby preventing the cyclic
nucleotide hydrolysis. Salmon calcitonin significantly
induced levels of cAMP in articular chondrocytes, see fig-
ure 3B. The concentrations of salmon calcitonin caused a
more than 100% increase in cAMP activation. A maximal
>200% induction in cAMP activation was observed by the
[1 nM] dose (P < 0.001) compared to [100 μM] IBMX.
Furthermore, blocking of the cAMP signaling was
investigated by competition of receptor binding by the
calcitonin receptor antagonist 8-32sCT. Binding of the
8-32sCT do not lead to a response in the second mes-
senger cAMP. Addition of the antagonist together with
the highest dose of salmon calcitonin (100 nM) caused a
50% (P < 0.001) reduction compared to calcitonin alone,
see figure 3C. The cAMP release was comparable to
IBMX levels when the antagonist was added to cultures
with or without salmon calcitonin (100 nM). The posi-
tive control forskolin significantly increased cAMP levels
(P < 0.001).
Cell viability in response to salmon calcitonin
To investigate whether salmon calcitonin has an effect
on cell number and metabolic activity, cell viability were
investigated by AlamarBlue in the explants culture at
the last day of culture. As the cells metabolize, the
redox-potential changes, which makes the metabolic dye
change color from blue to purple, thus allowing the via-
bility of the cells to be by quantified by fluorescence.
The fluorescence levels from metabolic inactivated carti-
lage corresponds to the background levels and was sig-
nificantly different from the control, P < 0.001, as seen
in figure 4. The treatments with salmon calcitonin did
not affect the cell viability significantly and thus the sal-
mon calcitonin not toxic to the chondrocytes. IGF did
not affect chondrocyte cell viability.
Discussion
These current data highlight that salmon calcitonin con-
centration-dependently and significantly stimulated pro-
teoglycan and collagen type II synthesis in human
osteoarthritic cartilage in vitro and validates that human
OA chondrocytes express the calcitonin receptor. Sal-
mon calcitonin has been demonstrated by different
research groups to have chondroprotective effects in a
range of animal models of OA, representing different
aspects of the disease. However, in respect to the docu-
mented preclinical efficacy, the precise mode of action
still remains to be evaluated.
The current experiments have provided evidence for a
potential anabolic effect of calcitonin on human osteoar-
thritic chondrocytes, both with respect to proteoglycan
and collagen type II synthesis. We used IGF as a posi-
tive control that previously has been shown to stimulate
cartilage formation [19]. The biochemical marker PIINP
was used for investigation of the direct effect of salmon
calcitonin on collagen type II formation [21]. Salmon
calcitonin stimulated cartilage synthesis to the same
level as the positive control, IGF. However, these data
highlight the small window of response in the current
line of experiments, and the smaller responsiveness of
old human articular cartilage [24] compared to that of
young bovine cartilage or other types of cartilage as pre-
viously observed [25]. We investigated proteoglycan
synthesis by the gold standard method, radio-labeled
incorporation of
35SO4. We found that salmon calcito-
nin dose-dependently increased proteoglycan incorpora-
tion into the matrix. These data are in alignment with
those presented by other groups, although the results
are from non-human models [12,26-30].
In the present studies we focused on the direct effect
of salmon calcitonin on human osteoarthritic cartilage,
as the effect on bone resorption and remodeling are
well understood and accepted [31]. We employed an
articular cartilage explants model in which the
Figure 2 Stimulation of human OA cartiage explants with
salmon caltionin increase the release of pro-peptides of type II
collagen. Human OA cartilage explants were cultured for 16 days
with different doses of salmon calcitonin and IGF as positiv control.
The released neoepitopes in the supernatant from day 16, were
quatifiened by an ELISA detecting the N-terminal collagen type II
pro-peptides, PIINP. The bars represent the mean value from 6-
replicates and the indivdual values were adjusted for the amount of
cultured cartilage. The errorbars are the standard error of mean,
SEM. The asterisk symbolize the levels of statistical difference to the
vehicle control, * P < 0.05. **P < 0.01.
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environment, which preserves chondrocyte phenotype
[32]. This may provide a different phenotype of chon-
drocytes compared to that of growth plate and mono-
layers of proliferating chondrocyte-like cells. It is
becoming more and more evident that the ECM geno-
type modulates the phenotype of cells [33] and by that
the cellular response to different stimuli.
Calcitonin has on previous occasions been shown to
have direct anabolic effects on cartilage, however this
was limited to hypertrophic chondrocytes in growth
plate cartilage of rats [29,34], and other development
cartilage forms in avian models [28,30,35]. Kato et al.
[36] demonstrated that calcitonin stimulated the sulfa-
tion of proteoglycans in isolated chondrocytes from rats
and rabbits. The response to calcitonin was investigated
Figure 3 Human chondrocytes express the calcitonin receptor. A. Calcitonin receptor expression in human osteoclasts and cartilage was
analyzed using QPCR. QPCR products were visualized on a 2% agarose gel. Lanes: 1+19 NEB 100 bp DNA ladder, 2-4 CalcR1, 5-7 CalcR2, 8-10
CalcR 3, 11-13 CalcR 4, 14-16 Surf 1, 17-18 Coll2a. Abbreviations: CalcR - calcitonin receptor primer pair 1-4; Coll2a - Collagen type II; HOC -
human osteoclasts; HCC - human chondrocytes; NTC - no template control. B. Intracellular cAMP levels after stimulation with salmon calcitonin:
Human OA chondrocytes were stimulated with IBMX for one hour, followed by 15 minutes stimulation in presence or absence of salmon
calcitonin as specified in the figure legends. C. Binding competition by the calcitonin receptor antagonist 8-32sCT. Forskolin was used as positive
control. The asterisks indicate significant differences (** P < 0.01, *** P < 0.001).
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was done in isolated chondrocytes cultured in clusters
without their ECM. Human articular chondrocytes from
OA patients may be different compared to that of devel-
opment models that includes, but are not limited to
composition of the matrix, age of the investigated cells
and natural differences among species. The current data
further aid in the understanding of the anabolic effects
of salmon calcitonin.
Many findings in the literature point toward a phar-
macological effect of calcitonin on chondrocytes
[26,35,37], but the response may not exclusively be
mediated by the calcitonin receptors. The calcitonin
receptors are promiscuous with respect to ligand bind-
ing. Thus, calcitonin, calcitonin gene-related peptide
(CGRP), adrenomedullin (AM) and amylin (AMY) are
able to displace each other from specific binding sites,
implying significant cross-reactivity of each of them
with the receptors of other peptides. Receptor activity-
modifying proteins (RAMPs) are single transmembrane
proteins that are critical to the calcitonin family G-pro-
tein coupled receptors for receptor-ligand recognition.
The calcitonin receptor has 60% homology to the calci-
tonin receptor-like receptor (CL), and the calcitonin
receptor predominantly recognizes calcitonin in the
absence of RAMPs. Alpha-CGRP, AM, and AMY are
also able to signal through the calcitonin receptor [38].
In the presence of RAMP 3, the calcitonin receptor only
interacts with AMY [39]. An AMY/CGRP receptor is
recognized when a calcitonin receptor is co-expressed
with RAMP 1. RAMP 1-transported CL is a CGRP
receptor. RAMP 2- or RAMP 3-transported CL are AM
receptors [40]. The CL is identified as a CGRP receptor
when co-expressed with RAMP 1. The same receptor is
specific for AM in the presence of RAMP 2. Thus, due
to the complex promiscuous properties of the calcitonin
family receptors it is not possible from the current
experiments to rule out signaling of salmon calcitonin
through the other receptors.
We indirectly investigated the binding of salmon calci-
tonin to the calcitonin receptor by examining the levels
of intracellular cAMP in isolated chondrocytes and
thereby the functionality of the receptor. Additionally
we show data that indicates that the cAMP induction of
salmon calcitonin could be completely blocked by an
antagonist to the calcitonin receptor, 8-32sCT. G-
coupled 7TM receptors have cAMP as a second messen-
ger and calcitonin is known to increase cAMP levels in
other cell types [23]. Our group has recently showed
that cAMP is an important determinant in directing
chondrocytes from a catabolic to an anti-catabolic shift
in phenotype [25]. These data are in alignment with
other findings suggesting cAMP may be part in an
important shift in chondrocyte phenotype [41,42]. These
findings are in alignment indicating that elevated levels
of cAMP play an important part in the shift into a more
cartilage producing anabolic cell phenotype. However,
this smaller elevation of cAMP may only be an inter-
mediate factor in the complex machinery of cellular sig-
naling pattern eventually leading to cartilage synthesis.
The cellular actions remain to be investigated and are
beyond the scope of this report.
The present data may be in alignment with those of
previous investigators, but not with the findings by Lin
et al. [10]. A recent report from the group showed that
the calcitonin receptor was not expressed in human
chondrocytes. However, this central contradiction may
be explained by important experimental differences. In
the current experiments mRNA was obtained from
freshly isolated articular cartilage, collected in RNALater
at the operation theater. In contrast, the chondrocytes
used by Lin et al. were not primary chondrocytes but
chondrocytes cultured in 20% serum until confluence, a
treatment known to change the chondrocyte phenotype
and make the cells dedifferentiate to a fibroblast-like
cell type and hence effect the gene expression. In dis-
agreement with the report by Lin et al. we show the
presence of this particular fragment in articular chon-
drocytes and additionally by three other primer pairs.
T h ed i f f e r e n c ei nt h e s ef i n d i n g sm a yb ed u et oQ P C R
sensitivity issues taking into account the low expression
of the calcitonin receptor in adult human cartilage. As
pointed out by the group, the expression of the calcito-
nin receptor may indeed be regulated by age, but may
also be influenced by the location in the cartilage
Figure 4 Chondrocyte viability. The chondrocyte viability was
investigated by the metabolic dye AlamarBlue and was by
quantified by fluorescence. The bars represent the mean value from
6-replicates at the last day of culture and the indivdual values were
adjusted for the amount of cultured cartilage. The errorbars are the
standard error of mean, SEM, and the asteriks indicate ***, P < 0.001.
Salmon calcitonin: sCT.
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in hypertrophic deep zones of the cartilage in pre-clini-
cal models [29]. We exclusively used articular cartilage
from the surface layer of the femur plateau. In addition,
there might be differences in the expression of the calci-
tonin receptor in healthy cartilage compared to cartilage
from OA patients. Further research may be needed to
understand the differences of expression patterns of
chondrocytes that may be highly related to their immedi-
ate phenotype. These subpopulation of chondrocytes
includes but are not limited to those affected by age, sex,
clinical history, and whether chondrocytes are hyper-
trophic, proliferating, matrix synthesizing and in addition
originate from weight bearing or non weight bearing
areas. The presented data showed expression of the calci-
tonin receptor at RNA-levels. However in a previous
publication we have also shown the expression of the
calcitonin receptor at protein levels by immunohisto-
chemistry in the upper zones of human OA articular car-
tilage with the chondrocytes embedded in the matrix [9].
Our investigations did not set out to quantitatively
evaluate the amount of the calcitonin receptor, but
merely to investigate its expression in human articular
chondrocytes. However, comparison between the
expression of the housekeeping gene Surf1 and that of
all calcitonin receptor amplicons based purely on Ct
values (~30 vs. ~36) clearly showed that the calcitonin
receptor is expressed in low levels. Thus, to ensure
QPCR detection, the method must be optimized, which
we obtained by use of a calcitonin receptor expressing
plasmid. Accordingly, we determined all SYBR Green
melting temperatures for the calcitonin receptor primer
p a i r sb yQ P C Ra n a l y s i so nap l a s m i de n c o d i n gt h e
entire calcitonin receptor. In the present study we inves-
tigated the calcitonin receptor expression in human
articular cartilage isolated directly without any prior cul-
turing. We have likewise examined the expression of the
calcitonin receptor using the same four primer pairs and
additionally in pronase- and collagenase-retrieved iso-
lated human chondrocytes pooled from four patients,
and were in all instances able to detect calcitonin
expression (data not shown). Of concern, multiple splice
variants of the calcitonin receptor exists in the same
organism, and at least four are recognized in humans, of
which one is located in the non-coding region of the
receptor [43,44]. Further research is needed to investi-
gate which splices variant or variants as well as their sig-
naling in human articular chondrocytes.
As mentioned in the introduction, OA involves
changes in the joint triadic: bone, cartilage and syno-
vium. It is still debated, which parameters are the initia-
tors or drivers of disease progression, although it is
becoming more clear that inflammation may not initiate
the disease but rather play an important role in the pro-
gression of the disease at later stages [4]. Intuitively the
chondroprotective effects of calcitonin may in part be
mediated through a direct action on chondrocytes and
in part through effects on subchondral bone remodeling
[4]. We have previously, under in vitro conditions,
shown that salmon calcitonin was able to decrease cyto-
kine-stimulated degradation in bovine articular cartilage
explants in connection to lowering of the proteolytic
activity and expression of MMPs [9]. The anti-catabolic
actions of calcitonin have been observed in isolated
human chondrocytes culturedi nc l u s t e r sb yF r a n c h i -
mont et al. [26]. Some researchers have found anti-
inflammatory effects of calcitonin, albeit these effects
remain to be further understood in relation to clinical
OA [45,46].
The putative effect of salmon calcitonin on the pro-
gression of OA has been investigated under clinical set-
tings and focused on the positive effects on cartilage
degradation [47,48]. In the context of the current data
in, which positive effects of cartilage formation was
observed, future studies might be undertaken to investi-
gate the effect on cartilage synthesis markers such as
PIINP or PIIAnP and thereby more optimally estimate
possible efficacy [32,47].
Conclusion
Calcitonin treatment increased proteoglycan and col-
lagen synthesis of human OA cartilage. Calcitonin may
provide additional positive effects on joint health
directly on articular chondrocytes in addition to the well
established osteoclast mediated effects on subchondral
bone.
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